The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
Open accessAbstract
Like human gliomas, the rat 9L gliosarcoma secretes the immunosuppressive transforming growth factor beta (TGF-beta). Using the 9L model, we tested our hypothesis that genetic modification of glioma cells to block TGF-beta expression may enhance their immunogenicity and make them more suitable for active tumor immunotherapy. Subcutaneous immunizations of tumor-bearing animals with 9L cells genetically modified to inhibit TGF-beta expression with an antisense plasmid vector resulted in a significantly higher number of animals surviving for 12 weeks (11/11, 100%) compared to immunizations with control vector-modified 9L cells (2/15, 13%) or 9L cells transduced with an interleukin 2 retroviral vector (3/10, 30%) (P < 0.001 for both comparisons). Histologic evaluation of implantation sites 12 weeks after treatment revealed no evidence of residual tumor. In vitro tumor cytotoxicity assays with lymph node effector cells revealed a 3- to 4-fold increase in lytic activity for the animals immunized with TGF-beta antisense-modified tumor cells compared to immunizations with control vector or interleukin 2 gene-modified tumor cells. These results indicate that inhibition of TGF-beta expression significantly enhances tumor-cell immunogenicity and supports future clinical evaluation of TGF-beta antisense gene therapy for TGF-beta-expressing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
Transforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M., Ding, A., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 861
The TGF-β family of growth and differentiation factors
Massagué, J. (1987) · Cell · doi:10.1016/0092-8674(87)90443-0 · Cited by 664
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., & Fontana, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3222 · Cited by 386
National survey of patterns of care for brain-tumor patients
Mahaley, M. S., Mettlin, C., Natarajan, N., Laws, E. R., & Peace, B. B. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.6.0826 · Cited by 383
Wrann, M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., & Fontana, A. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02411.x · Cited by 332
Trojan, J., Johnson, T. R., Rudin, S. D., Ilan, J., Tykocinski, M. L., & Ilan, J. (1993) · Science · doi:10.1126/science.8418502 · Cited by 329
Alleva, D. G., Burger, C. J., & Elgert, K. D. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1674 · Cited by 241
Modulation of T-cell function by gliomas
Roszman, T., Elliott, L., & Brooks, W. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90068-5 · Cited by 234
Pisa, P., Halapi, E., Pisa, E. K., Gerdin, E., Hising, C., Bucht, A., Gerdin, B., & Kiessling, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7708 · Cited by 231
Growth factor production by human colon carcinoma cell lines.
Anzano, M. A., Rieman, D. J., Prichett, W. P., et al. (1989) · PubMed · Cited by 186
Trojan, J., Blossey, B. K., Johnson, T. R., Rudin, S. D., Tykocinski, M., Ilan, J., & Ilan, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4874 · Cited by 176
Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study
Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., & Thompson, T. C. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90055-l · Cited by 167
Lowest dose interleukin-2 immunotherapy [see comments]
Smith, K. (1993) · Blood · doi:10.1182/blood.v81.6.1414.bloodjournal8161414 · Cited by 161
Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice.
Fontana, A., Frei, K., Bodmer, S., Hofer, E., Schreier, M. H., Palladino, M. A., & Zinkernagel, R. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3230 · Cited by 160
Introduction and expression of DNA molecules in eukaryotic cells by electroporation.
Andreason, G. L., & Evans, G. A. (1988) · PubMed · Cited by 155
Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2
Kuppner, M. C., Hamou, M., Sawamura, Y., Bodmer, S., & de Tribolet, N. (1989) · Journal of neurosurgery · doi:10.3171/jns.1989.71.2.0211 · Cited by 150
Hanks, S. K., Armour, R., Baldwin, J. H., et al. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.1.79 · Cited by 131
Rimolid, D., Romero, P. A., & Carrel, S. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540329 · Cited by 86
Huber, D., Philipp, J., & Fontana, A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.1.277 · Cited by 81
Hirte, H. W., & Clark, D. A. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01789047 · Cited by 71
Ruffini, P. A., Rivoltini, L., Silvani, A., Boiardi, A., & Parmiani, G. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01742258 · Cited by 61
Expression of transforming growth factor beta mRNA isoforms in human breast cancer
MacCallum, J., Bartlett, J., Thompson, A., Keen, J., Dixon, J. M., & Miller, W. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.197 · Cited by 50
A novel, sensitive bioassay for transforming growth factor β
Randall, L. A., Wadhwa, M., Thorpe, R., & Mire‐Sluis, A. R. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90276-d · Cited by 31
Hirte, H. W., Clark, D. A., O'Connell, G. J., et al. (1992) · Cellular Immunology · doi:10.1016/0008-8749(92)90281-s · Cited by 25
Cited by
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Clonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Metadata
- Authors
- Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., & Sobol, R. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-04-02
- Volume
- 93
- Issue
- 7
- Pages
- 2909-2914
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2058006748
- Cited by
- 334
- References
- 31
- FWCI
- 24.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.